<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164909">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02035397</url>
  </required_header>
  <id_info>
    <org_study_id>2013/1597</org_study_id>
    <secondary_id>2012-004381-18</secondary_id>
    <nct_id>NCT02035397</nct_id>
  </id_info>
  <brief_title>Botox-treatment of Morbid Obesity</brief_title>
  <official_title>Treatment of Morbid Obesity by Intragastric Injections of Botulinum Toxin A. A Randomized, Double-blind, Placebo Controlled, Phase II-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <authority>Norway:National Committee for Medical and Health Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One possible angle for treating obesity could be slowing down the gastric emptying time. By
      prolonging the gastric emptying time, the person would ideally experience increased
      sensation of satiety, and in the long run reduce food intake. If such a treatment provides a
      clinically significant weight loss, this could be an alternative for surgical procedures,
      avoiding the risk for perioperative complications as well as complications in the long run.

      There are now several pilot studies documenting that intragastric treatment with botulinum
      toxin A (BTA) can be effective, although the treatment perspective is short and do not
      include repeated injections. However, they demonstrate that BTA-injections are safe for the
      patient. The treatment is administered by endoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>Change from baseline to 6 months; 1 year; 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity, Morbid</condition>
  <arm_group>
    <arm_group_label>botox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botox injection in muscles of stomach wall</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injection first 6 months, then active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botox injection</intervention_name>
    <arm_group_label>botox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo injection</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt; 35

        Exclusion Criteria:

          -  Known hypersensitivity to medication

          -  Neuro muscular disease

          -  Dysphagia

          -  Tendency for aspiration

          -  Ulcus

          -  Use of aminoglycoside antibiotics and/or spectinomycin lately

          -  Previous side effects of botox injections

          -  Previous bariatric surgery

          -  Previous cancer in GI-tract

          -  Other obesity treatment last 12 months

          -  Severe eating disorder

          -  Hypothyroidism

          -  Pregnancy/brest feeding

          -  Reduced competence to consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bård Kulseng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magnus Strømmen, MSc</last_name>
    <email>magnus.strommen@stolav.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Olavs Hospital, Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gjermund Johnsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronald Mårvik, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Duan Chen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>January 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>botulinum toxin</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Satiation</keyword>
  <keyword>Diet</keyword>
  <keyword>Weight Loss</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
